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Interleukin-6 (IL-6) is an inflammatory cytokine whose levels increase significantly during myocardial infarction (MI).
It has been hypothesised that the concentrations of IL-6 at admission may be useful in prognosticating long-term
outcomes. It is unclear, however, whether IL-6 could improve the prognosis of early mortality in MI.
We have compared serum IL-6 levels and analysed the disease course in 158 patients with ST-elevation MI (STEMI)
who either survived (n = 148) or died (n = 10) within 30 days following the admission. Patients were treated in a
single university centre with primary percutaneous coronary intervention (PCI).
The non-survivors (6.3%) displayed most of typical risk factors for poor outcome. In addition they had significantly
higher concentrations of IL-6 at hospital admission (median values 8.5 vs. 2.0 pg/ml; p = 0.038). However, they
were also significantly older than the survivors (median values 72 vs. 57 years; p = 0.0001). IL-6 levels are known to
increase with age and we could confirm a significant correlation between patients’ calendar age and circulating
IL-6 (p = 0.009). Regression analysis revealed that IL-6 concentrations were significantly affected by patients’ age but
they did not independently relate to patients’ outcome.
Such results indicate that circulating IL-6 at admission may be of limited value in predicting early mortality in STEMI.
It is important to recognize that, because of the small group of patients who died (N = 10), the results must be
interpreted with caution. Therefore, we stress that these results should be viewed as preliminary and further
validated in a larger set of patients.
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IL-6 is a key mediator of inflammation [1,2] and as such
has been implicated in the pathogenesis of atheroscler-
osis and coronary artery disease (CAD) [3]. Biological ef-
fects of IL-6 are mediated either by classic IL-6 receptor
(IL-6R) or by trans-signalling via soluble IL-6R (sIL-6R)
[4]. Positive associations between circulating IL-6 con-
centrations and the risk of CAD have been consistently
observed [5]. Mendelian randomization studies indicate
there might exist causal association between signalling
through IL-6R and CAD [6].* Correspondence: dkanikowska@ump.edu.pl
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article, unless otherwise stated.Moreover, results of several studies suggest that high
IL-6 levels during acute coronary syndromes (ACS) may
be associated with worse long-term prognosis [7-13].
Less clear is the link between IL-6 and early mortality in
ACS. On the one hand, high IL-6 was proposed to pre-
dict 30-day mortality in patients with cardiogenic shock
after myocardial infarction [14,15]. On the other hand,
the association of high baseline IL-6 concentrations with
increased mortality within 16 weeks after ACS became
insignificant when adjusted for known covariates [9].
Chronologic age is a strong independent risk factor for
increased morbidity and mortality from ACS [16,17].
The role of age as a covariate may be of particular im-
portance in interpreting IL-6 data. It is because ageing isntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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related both to an increased prevalence of cardiovascular
risk factors and to ageing per se [18,19]. The relative
contribution of these process is difficult to estimate and
differs probably between the populations studied.
We thought we could add to this debate by examining
if serum levels of IL-6 recorded at admission predict
30-day mortality in patients with myocardial infarction.
Experimentally, such a study would require groups of
patients who had been controlled for age and other risk
factors, including duration of CAD. However, in prac-
tice, this would be very difficult to achieve. Accordingly,
the effect of such factors has been taken into account
statistically.
Material and methods
Samples from 158 patients with acute ST-elevation myo-
cardial infarction (STEMI) were analysed. Blood samples
were taken in the acute phase of STEMI on admission
to the hospital and before primary PCI. The diagnosis
was based on typical clinical, biochemical, and electrocar-
diographic criteria. All patients underwent primary percu-
taneous coronary intervention (PCI) within 12 hours after
the onset of chest pain. The procedure was performed
according to standard institutional practices with stenting
whenever possible. After PCI the patients were maintained
on standard dual anti-platelet therapy (aspirin, clopido-
grel), β-blockers, and angiotensin-converting enzyme
inhibitors. Statins (atorvastatin or simvastatin) were in-
troduced 48 hours after PCI. Patients with pre-existing
autoimmune or inflammatory disease, malignancy, im-
munosuppression, and prior therapy with statins were
not included in the analysis, as these conditions may
independently affect IL-6 levels.
IL-6 and sIL-6R were measured with enzyme-linked
immunosorbent assay using DuoSet Development kits
(R&D Systems, USA). The assays were performed as
per manufacturer’s instructions. Sensitivity of the as-
says, as calculated by adding two standard deviations
to the mean read-out for blank samples (n = 16), was
2 pg/ml and 9 pg/ml for IL-6 and sIL-6R, respectively.
To enable logarithmic transformation, values below
the limit of detection were assigned a value of 0.1 ra-
ther than zero.
Statistical analyses were performed using SPSS v.20
software (IBM, USA). The comparisons were made be-
tween patients who either survived or died within
30 days after STEMI. The normally distributed data
were analysed using t-tests and Pearson’s correlation;
the data that were not distributed normally were com-
pared using Mann-Whitney’s U-test and Spearman’s
correlation. For regression analysis, the abnormally
distributed data were log transformed. In this analysis,
possible confounders (age and length of time beforethe cardiac event that CAD had been experienced)
were incorporated in order to focus upon the issue of
whether or not the variables of interest were associ-
ated with patient survival. Categorized data were ana-
lysed with the Fisher’s test. The level of significance
was set at P < 0.05.Ethical approval
Ethics Committee of the Poznan University of Medical
Sciences.Results
Of 158 STEMI patients analysed, 10 (6.3%) died within
30 days. Eight deaths occurred during initial hospitalization
and were related to either cardiogenic shock (7 patients) or
ventricular fibrillation (1 patient). The characteristics of
patients from the two groups are listed in Table 1. Mean
time from the onset of pain to PCI (total ischemic time) in
survivors was 4.2 +/− 2.6 hours and in non-survivors was
7.1 +/− 2.0 hours (p < 0.001).
The differences observed were not unexpected and in-
cluded rather predictable parameters, such as age, time
to treatment, long-term multiple-vessel CAD, high
Killip-Kimball class, higher CPK, in-hospital events, and
complicated PCI [20]. Interestingly, the levels of IL-6 at
admission were significantly higher in patients who
subsequently died compared with those who survived.
Concentrations of sIL-6R did not differ between the
groups.
The above data suggested that high IL-6 concentra-
tions might be predicting early mortality in STEMI.
However, patients who died were also significantly older
(57.8 ± 0.9 vs. 72.6 ± 2.3 years). Serum IL-6 levels are
known to increase with age [18] and, indeed, such a
correlation was evident also in our patient population
(Spearman r = 0.2047, p = 0.009; Figure 1). Therefore,
the difference in IL-6 observed had to be corrected for
age in order to determine whether it could be specific-
ally related to patients’ outcome. To this end, a regres-
sion analysis was performed using age and outcome
(treated as a dichotomous variable with “0” and “1” for
survivors and non-survivors, respectively) as the pre-
dictors. Values of log [IL-6] were predicted signifi-
cantly in this model (F2,155 = 4.72, p = 0.01). The
standardized beta-coefficient for age was positive and
significant (p = 0.042), whereas that for outcome was
positive (higher in those who died) but not signifi-
cantly so (p = 0.139) (Table 2). In addition, even
though CAD was 2.6x more prevalent in patients who
died than in those who survived (P = 0.014, t-test), in-
corporating prior duration of CAD into the regression
equation showed that it was not a significant predictor
(P = 0.54) and the results were, essentially, unchanged.
Table 1 Patient characteristics
Survivors (n = 148) Non-survivors (n = 10) P
Demographic parameters
Age, yrs 57 (50–64) 72 (68–80) 0.0001
Gender (men,%) 70 72 1.00
BMI (kg/m2) 26.0 (24.1-28.0) 25.0 (21.0-26.8) 0.27
Medical history
Hypertension,% 45 45 1.00
Diabetes,% 13 20 0.63
Smoking,% 65 30 0.042
Previous angina,% 20 70 0.0006
Prior MI,% 9 0 0.60
Current disease
Time to treatment, hrs 3.5 (2.5-5.0) 7.0 (4.0-9.0) 0.003
Max. QRS duration, ms 90 (80–100) 100 (93–120) 0.60
EF,% 61 (50–72) 56 (45–63) 0.003
Killip-Kimball class >1,% 3 64 0.0001
Angiographic parameters
>1 vessel affected,% 47 90 0.016
TIMI (0–2) before PCI,% 93 100 1.00
TIMI (0–2) after PCI,% 32 60 0.091
CTFG 24 (30–32) 25 (31–100) 0.019
MBG (0–1),% 32 60 0.091
Abciximab,% 26 70 0.008
PCI complications,% 5 40 0.009
Laboratory findings
CPK, U/l 1649 (740–2699) 3473 (2544–4885) 0.011
CK-MB, U/l 159 (62–273) 371 (271–520) 0.014
cTnI (μg/l) 16 (3–45) 7 (1–30) 0.62
Total cholesterol, mmol/l 5.9 (5.2-7.2) 6.2 (5.6-6.8) 0.78
LDL cholesterol, mmol/l 3.9 (3.2-4.8) 3.9 (3.4-4.4) 0.93
HDL cholesterol, mmol/l 1.4 (1.2-1.7) 1.3 (1.1-1.7) 0.64
Triglycerides, mmol/l 1.5 (1.1-2.2) 1.6 (0.9-2.6) 0.93
Glucose, mmol/l 6.4 (5.6-7.7) 9.3 (7.3-14.1) 0.002
CRP (mg/l) 2.2 (0.7-6.3) 2.0 (1.3-6.0) 0.74
Creatinine, μmol/l 84 (73–96) 94 (74–127) 0.26
IL-6, pg/ml 2.0 (0.1-9.0) 8.5 (2.5-20.0) 0.032
sIL-6R, ng/ml 53.0 (41.6-66.2) 51.1 (32.9-65.1) 0.58
Abbreviations: BMI body mass index, CK-MB creatine kinase-myocardial band isoform, CPK creatine phosphokinase, CRP C-reactive protein, CTFC corrected TIMI
frame count, EF ejection fraction, HDL high density lipoprotein, IL-6 interleukin-6, IL-6sR interleukin-6 soluble receptor, LDL low density lipoprotein, MBG myocardial
blush grade, TIMI thrombolysis in myocardial infarction scale.
Comparisons were made between patients who survived and those who died within 30 days after STEMI. Values are the medians (and interquartile ranges)
or percentages.
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method of correcting for age. For this analysis only
those survivors were selected (n = 17), who were of the
same age as those who died (59, 67, 68, 72, 77, 80 and83 years). This approach made the two groups more
similar in age and number (Table 3). Levels of IL-6, log
[IL-6] and sIL-6RS in these groups were not at all sig-
nificantly different.
Figure 1 Correlation between age and serum log [IL-6]
concentration. Survivors – closed symbols; non-survivors –
open symbols.
Table 3 Comparison of survivors and non-survivors of
similar age
Survivors (n = 17) Non-survivors (n = 10) P
Age, yrs 69.1 ± 1.8 72.6 ± 2.3 0.25
Log [IL-6], pg/ml 0.46 ± 0.28 0.84 ± 0.28 0.31
sIL-6R, ng/ml 51.6 ± 4.5 50.5 ± 4.9 0.86
Only survivors of the same age as non survivors were analysed. Values are
presented as means ± SE.
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centration had been significantly affected by patients’
age but not independently by patients’ outcome.
Discussion
Increased levels of IL-6 found in the elderly reflect pre-
dominantly an increased prevalence of cardiovascular risk
factors or subclinical cardiovascular abnormalities, and
the presence of other age-related diseases. Nevertheless,
the rise in IL-6 with age is seen even after adjusting
for these variables, which may suggest there exists
an age-associated dysregulation of IL-6 production
[18,19,21,22]. Therefore, the interpretation of increased
IL-6 concentrations in the elderly in the context of CAD
may be difficult. On the one hand, age-related increase in
pro-inflammatory cytokines may pave the way for the
disease; on the other hand it may blur a disease-specific
increase in cytokine release.
Older individuals with low risk profile might have
been under-represented in some studies. When, however,
the elderly population is more specifically targeted, theTable 2 Predictors of serum log [IL-6] in STEMI
Model Unstandardized coefficients
B Std. Error
1 Constant -.841 .457
Age .016 .008
Outcome .521 .350
Dependent Variable: Log [IL6].
Regression analysis was performed using age and outcome [survived vs. died] as thIL-6 assessment appears to improve long-term prediction
of future CAD events [23]. It needs to be determined
whether the same holds true for early mortality after
STEMI. Although our observations indicate it might not
always be the case, more well-powered studies would be
required.
Including the prior duration of CAD in the regression
calculation showed that it was not a significant predictor
of patient outcome. Furthermore, we chose to analyse
only patients with no history of previous therapy with
statins as they are known to damp inflammation and
decrease IL-6 release [24,25]. It would be interesting to
determine whether earlier exposure to statins impacts
on the value of IL-6 (or the lack of it) in predicting
early mortality in patients with STEMI treated with
primary PCI.
It is accepted that, because of the small group of
patients who died (N = 10), care must be taken with
interpreting the results, whether they are statistically sig-
nificant (when a larger sample is required to confirm
this difference) or non-significant (when a Type II error
might be present). Therefore, any interpretation of the
present results must be considered speculative, and need
to be confirmed in a larger set of patients.
For the moment, the results of our small single-centre
study suggest that high IL-6 levels observed at baseline
in non-survivors are related more to their advanced
aged rather than point independently to an increased
risk of early death. It is accepted that percutaneous cor-
onary intervention (PCI) and coronary artery bypass
grafting (CABG) are both good options for patients with
advanced CAD [26]. Nevertheless, the challenge of
finding optimal markers of long-term prognosis in such
patients remains. The present study indicates that levels
of IL-6 do not seem to be sufficiently disciminatory in
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